Highlights

  • CSL (ASX:CSL) shares traded at AUD 171.94, down 1.12% at the time of writing on 28 August 2026.
  • The company reported FY26 Revenue of US$15.8 billion and underlying NPATA of US$3.1 billion.
  • CSL continued its transformation program while strengthening its plasma, Vaccine and biotechnology operations.
  • Investors are monitoring plasma market trends, operational improvements and the company’s pipeline of future therapies.

CSL Limited (ASX:CSL) remained in focus within the Australian healthcare sector, with shares trading at AUD 171.94, down 1.12% at the time of writing on 28 August 2026. The company continues to attract investor attention following its FY26 results, which outlined a year of operational changes, restructuring initiatives and efforts to position the Business for future growth.

The broader Australian market was trading higher, with the S&P/ASX 200 (ASX:XJO) at 9,074.40 points, up 0.40% (+36.20) today. The S&P/ASX 300 (ASX:XKO) was trading at 9,006.20 points, up 0.39% (+34.80). Within the healthcare sector, the S&P/ASX 200 Health Care (ASX:XHJ) index was trading at 31,753.60 points, down 0.12% (-38.80).

Daily share price movements can reflect investor sentiment, market positioning and broader sector conditions. However, short-term price changes alone do not necessarily indicate changes in a company’s underlying fundamentals.

FY26 Performance

CSL reported its FY26 results for the year ended 30 June 2026, describing the period as a reset year focused on improving efficiency, simplifying operations and creating a pathway towards sustainable growth. The company reported total revenue of US$15.797 billion, up 2% compared with the previous year.

Underlying NPATA attributable to Equity holders was US$3.098 billion, down 4% on the prior corresponding period, while reported NPAT was a loss of US$2.579 billion following significant impairments and restructuring-related charges.

The company generated US$3.5 billion in Cash Flow from operations and maintained total FY26 Dividend payments at US$2.92 per share. CSL also completed a A$1 billion share buy-back program during the year.

CSL stated that transformation initiatives had progressed during FY26, with approximately US$176 million in cost savings achieved by the end of the financial year.

Business Overview

CSL is a global biotechnology company focused on developing and delivering therapies and vaccines for serious and complex medical conditions.

The company operates through three major businesses: CSL Behring, CSL Seqirus and CSL Vifor.

CSL Behring remains the largest contributor to group revenue, focusing on plasma-derived therapies, including immunoglobulin treatments, therapies for bleeding disorders and rare disease treatments. CSL Seqirus operates in influenza vaccines and Pandemic preparedness, while CSL Vifor focuses on iron deficiency and kidney-related therapies.

During FY26, CSL Behring generated revenue of US$11.387 billion, CSL Vifor contributed US$2.379 billion and CSL Seqirus delivered revenue of US$2.031 billion.

The company’s integrated model across plasma collection, Manufacturing and commercial operations remains a key part of its competitive positioning within global healthcare markets.

Therapy Growth

Plasma therapies continue to represent an important growth opportunity for CSL, with Demand for immunoglobulin treatments remaining a Key Industry trend.

CSL Behring reported immunoglobulin sales of US$6.2 billion during FY26, with performance affected by US channel inventory normalisation, Medicare Part D changes and previous tender impacts.

The company also highlighted progress from newer therapies. HEMGENIX sales increased 25%, while ANDEMBRY achieved US$240 million in its first full year in the market.

Within CSL Seqirus, seasonal influenza vaccine sales increased 4%, supported by products including FLUAD and FLUCELVAX. FLUAD sales reached US$968 million, up 5%, while FLUCELVAX sales increased 5% to US$503 million.

These areas remain important as CSL seeks to balance established products with newer therapies that can contribute to future growth.

Transformation Focus

A key focus for CSL has been improving operational efficiency and simplifying its organisational structure.

The company continued its transformation program during FY26, including the integration of CSL Behring and CSL Vifor commercial and medical affairs activities. CSL stated that the program helped reduce complexity and improve decision-making processes.

CSL also announced plans to invest approximately US$1.5 billion to expand its US plasma manufacturing presence, including the Horizon 2 Yield improvement program.

The company recognised significant impairments during FY26, including pre-tax impairments of US$7.1 billion for the year. These were primarily associated with changes in commercial outlook, generic competition timing, regulatory developments and market conditions.

Investors are likely to assess whether these restructuring actions can support improved efficiency and create a stronger platform for future Earnings growth.

Investor Focus

Investors tracking CSL are monitoring several factors, including plasma collection trends, therapy demand, vaccine performance, regulatory developments and execution of the transformation program.

The plasma industry remains an important area of focus due to increasing global demand for immunoglobulin therapies and specialised treatments.

CSL expects FY27 revenue to be broadly in line with the prior year and underlying NPAT growth of approximately 5% at FY26 exchange rates. CSL Behring is expected to deliver mid-single-digit revenue growth, supported by immunoglobulin demand.

The company is also focused on strengthening its manufacturing capacity and expanding its pipeline through research, partnerships and commercial development.

For healthcare investors, CSL’s ability to convert its global infrastructure, scientific expertise and product portfolio into sustainable earnings growth remains a key area of assessment.

Sector Outlook

The healthcare sector continues to experience long-term demand growth driven by ageing populations, advances in biotechnology and increasing demand for specialised therapies.

However, global healthcare companies also face challenges including regulatory changes, pricing pressures, manufacturing complexity and competitive dynamics.

CSL’s diversified exposure across plasma therapies, vaccines and specialty healthcare products provides multiple growth avenues. The company’s future performance will depend on execution across these businesses and its ability to improve operational efficiency.

The ongoing focus on innovation, manufacturing Investment and therapy development remains central to CSL’s long-term strategy.

Final Takeaway

CSL (ASX:CSL) shares traded at AUD 171.94, down 1.12% at the time of writing on 28 August 2026, as investors assessed the company’s FY26 performance and future growth strategy.

The company reported US$15.8 billion in revenue and US$3.1 billion in underlying NPATA during FY26, while continuing its transformation program and investing in future healthcare capabilities.

Daily share price movements do not necessarily represent changes in business fundamentals. Investors generally consider broader factors including financial performance, therapy growth, operational execution and long-term healthcare trends.